Tag: Prescription Drugs

Improvement seen in Unified Huntington's Disease Rating Scale Total Maximal Chorea with valbenazine versus placebo

No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib

Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care

Improvement in radiographic progression-free survival seen for talazoparib plus enzalutamide as first-line treatment

Findings seen for weekly semaglutide versus daily liraglutide regardless of procedure type

Improvement of one or more BMI category seen for majority of participants receiving semaglutide

Mean quality-of-life symptoms favor spironolactone at 12 and 24 weeks; more participants report acne improvement with spironolactone

Reduces 30-day risk for hospitalization and death, while only death was reduced in association with molnupiravir

Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo

Findings seen in patients with hormone receptor-positive advanced breast cancer with relapse, progression during aromatase inhibitor treatment